Gene · 79188
Papers1,602
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,602
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis. | J Breast Cancer | 2023 | 37565929 | PubTator, text mining | PubMed |
| Genetic Risk Stratification in Arrhythmogenic Left Ventricular Cardiomyopathy. | Card Electrophysiol Clin | 2023 | 37558308 | PubTator, text mining | PubMed |
| The Novel Variant NP_00454563.2 (p.Glu259Glyfs*77) in Gene PKP2 Associated with Arrhythmogenic Cardiomyopathy in 8 Families from Malaga, Spain. | Genes (Basel) | 2023 | 37510372 | PubTator, text mining | PubMed |
| Desmosomal Arrhythmogenic Cardiomyopathy: The Story Telling of a Genetically Determined Heart Muscle Disease. | Biomedicines | 2023 | 37509658 | PubTator, text mining | PubMed |
| Clinically actionable secondary findings in 130 triads from sub-Saharan African families with non-syndromic orofacial clefts. | Mol Genet Genomic Med | 2023 | 37496383 | PubTator, text mining | PubMed |
| Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer. | Front Mol Biosci | 2023 | 37484531 | PubTator, text mining | PubMed |
| Exercise does not influence development of phenotype in PLN p.(Arg14del) cardiomyopathy. | Neth Heart J | 2023 | 37474840 | PubTator, text mining | PubMed |
| ForestSubtype: a cancer subtype identifying approach based on high-dimensional genomic data and a parallel random forest. | BMC Bioinformatics | 2023 | 37468832 | PubTator, text mining | PubMed |
| Loss of epigenetic suppression of retrotransposons with oncogenic potential in aging mammary luminal epithelial cells. | Genome Res | 2023 | 37463750 | PubTator, text mining | PubMed |
| Catalytic antibodies in arrhythmogenic cardiomyopathy patients cleave desmoglein 2 and N-cadherin and impair cardiomyocyte cohesion. | Cell Mol Life Sci | 2023 | 37450050 | PubTator, text mining | PubMed |
| Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks. | Cell Death Dis | 2023 | 37438342 | PubTator, text mining | PubMed |
| The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. | J Exp Clin Cancer Res | 2023 | 37434266 | PubTator, text mining | PubMed |
| Application of next generation sequencing in cardiology: current and future precision medicine implications. | Front Cardiovasc Med | 2023 | 37424920 | PubTator, text mining | PubMed |
| Evolving cardiovascular genetic counseling needs in the era of precision medicine. | Front Cardiovasc Med | 2023 | 37424912 | PubTator, text mining | PubMed |
| Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers. | Nat Commun | 2023 | 37419892 | PubTator, text mining | PubMed |
| A Systematic Analysis of the Clinical Outcome Associated with Multiple Reclassified Desmosomal Gene Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Patients. | J Cardiovasc Transl Res | 2023 | 37418234 | PubTator, text mining | PubMed |
| CMA mediates resistance in breast cancer models. | Cancer Cell Int | 2023 | 37407979 | PubTator, text mining | PubMed |
| Estrogen-Induced LncRNA, LINC02568, Promotes Estrogen Receptor-Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms. | Adv Sci (Weinh) | 2023 | 37404090 | PubTator, text mining | PubMed |
| FOXK2 amplification and overexpression promotes breast cancer development and chemoresistance. | bioRxiv | 2023 | 37398114 | PubTator, text mining | PubMed |
| Dissecting molecular, pathological, and clinical features associated with tumor neural/neuroendocrine heterogeneity. | iScience | 2023 | 37378310 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79188/papers?page=9